MAPK3 and ductal breast carcinoma in situ: We demonstrated that activation of iFGFR1 robustly upregulates TNFAIP3 mRNA and protein in DCIS-iFGFR1 cells and this upregulation can be completely blocked by either FGFR inhibitors or ERK1/2 inhibitors.